Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment
Authors' conclusion
The assessment of disease activity, together with patients' and physicians' perceptions, form a key element in the correct discrimination of patients who are going to develop D2TRA-inefficacy. However, identifying those patients who will be D2TRA-other remains challenging, whether by subjective or objective parameters.
Study context
- Population
- Patients with rheumatoid arthritis (RA) starting b/tsDMARD treatment, 2020 to 2022
- Participants
- 255 patients
- Exposure
- Difficult-to-treat rheumatoid arthritis (D2TRA)-inefficacy vs D2TRA-other vs NoD2TRA
- NoD2TRAn = 167reference
- D2TRA-inefficacyn = 58
- D2TRA-othern = 30
- Outcome
- Trajectories of DAS28, PGA and PhGA and their capability to predict D2TRA classification
- Follow-up
- First 24 months of b/tsDMARD treatment
Methodological detailslatent class mixed models
- Latent class mixed models
Main finding
As reported in the abstract
Trajectories of DAS28, PGA and PhGA (latent class mixed models (LCMM)) · first 24 months
- Two trajectories for DAS28 and physician global assessment (PhGA), three for patient global assessment (PGA)
- Most notable variation in the first 6 months of treatment, stable thereafter
- Most D2TRA-inefficacy patients fitted the trajectory with higher values
- NoD2TRA followed the trajectory with lower values
- D2TRA-other distributed more homogeneously across all trajectories
Observational data: associations, not effects.
Original publication
Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment. RMD Open. Published 28 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →